The session provides a comprehensive update on the multidisciplinary management of head and neck cancers, focusing on advancements in radiotherapy. It will begin with an overview of the epidemiology and risk factors for oropharyngeal, laryngeal, hypopharyngeal, nasopharyngeal and cutaneous malignancies. It will highlight global trends such as the rising incidence of HPV-associated oropharyngeal cancer and the global variations in head and neck cancer subtypes.

The role of radiotherapy is highlighted in each disease site, emphasizing key management principles by incorporating the most recent data to guide evidence-based decisions. A general overview summarizing the key fractionation and systemic therapy trials precedes the individual disease sites. For oropharyngeal cancers, recent results from de-escalation studies will be discussed to guide contemporary standards of care. Patient selection for upfront surgery or radiation will also be a key learning objective. For laryngeal and hypopharyngeal cancers, discussions will address the integration of chemotherapy and radiation to preserve voice and swallowing function. Updates on nasopharyngeal cancer will focus on recent advancements in radiotherapy dosing, contouring and planning, and the role of systemic therapy. The management of cutaneous malignancies covers emerging data on adjuvant radiotherapy for high-risk tumors and its integration with immunotherapy.

Throughout, the lecture emphasizes patient-centered care, incorporating quality-of-life considerations and survivorship challenges into treatment decision making. Insights into optimizing radiation therapy planning and delivery will also be highlighted. This session is essential for clinicians aiming to provide cutting-edge, evidence-based care to patients with head and neck cancers.